Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Launched by M.D. ANDERSON CANCER CENTER · Jul 19, 2018

Keywords

ClinConnect Summary

This clinical trial is testing a new imaging technique using a special radioactive agent called Fluorine F 18 fluorthanatrace, or [^18F] FTT, to help doctors see solid tumors more clearly in women with certain types of cancer, including breast, ovarian, and fallopian tube cancers. The goal is to find out how well this imaging method works in spotting tumor cells that might be missed by other imaging tests.

To participate in this trial, women aged 65 to 74 with a known or suspected solid tumor and at least one tumor that is 1 cm or larger visible on standard imaging tests may be eligible. Participants will receive an injection of the radioactive tracer, followed by scans that create detailed pictures of the inside of their bodies. It's important to note that pregnant or breastfeeding women cannot take part, and those who are unable to undergo imaging procedures due to health reasons may also be excluded. This study is currently looking for volunteers, and it offers a potential opportunity to help improve cancer detection methods.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • History of known or suspected solid tumor.
• • At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \[CT\], magnetic resonance imaging \[MRI\], ultrasound, fludeoxyglucose \[FDG\] PET/CT).
• Exclusion Criteria:
• • Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \< 2 weeks prior to screening as standard of care.
• • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
• • Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.